Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Piramal Trims Research To Build Companions Of Neuraceq

This article was originally published in PharmAsia News

Executive Summary

Piramal Lifesciences has cut its research focus, eliminating drugs in the early stage development. Instead, the company will build on products that can be “companion products” to its newly launched flagship brand Neuraceq, used to detect symptoms associated with Alzheimer’s disease.

You may also be interested in...



India’s Piramal Ropes In Big Pharma Heavyhitters To Support Late-Stage R&D

MUMBAI - A progressively maturing pipeline of innovative compounds has led Piramal Healthcare Ltd. to begin adding leadership positions to its core research team. Piramal is believed to be drawing senior-level executives from established global companies in functions like drug discovery, development, international regulatory affairs and marketing strategies to ramp up expertise in late-stage processes

Ajay Piramal Aims At Lead Ranks In CRAMS, OTC And Critical Care Business; Reveals Details On Abbott Deal

MUMBAI - Giving up one flourishing unit seems to have created larger business opportunities for a few others that form part of Indian industrialist Ajay Piramal's enterprise Piramal Healthcare

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC088016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel